The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of apixaban versus other direct oral anticoagulants and low-molecular-weight-heparins for cancer associated venous thromboembolism in Spain.
 
Andres J. Muñoz Martín
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Pfizer; Celgene; Daiichi Sankyo; Incyte; LEO Pharma; Lilly; MSD Oncology; Roche; Sanofi
Speakers' Bureau - Rovi
Research Funding - LEO Pharma; Sanofi
Patents, Royalties, Other Intellectual Property - Risk assessment model in venous thromboembolism in cancer patients
Travel, Accommodations, Expenses - Amgen; Celgene; Merck Serono; Roche
 
Enrique Gallardo Díaz
No Relationships to Disclose
 
Carlos Crespo
Consulting or Advisory Role - Pfizer
 
Roma Masana Domenech
No Relationships to Disclose
 
Javier Soto
Employment - Pfizer
 
Daniel Arumi
Employment - Pfizer
 
Susana Fernandez
Employment - Pfizer